Who is sponsoring NCT02143024?

NCT02143024 is sponsored by University of California, Davis.

What drugs are being tested in NCT02143024?

Interventions in NCT02143024: Family-based depression intervention, Usual care plus educational materials.

What condition does NCT02143024 study?

NCT02143024 studies Major Depression.

Is NCT02143024 still recruiting?

NCT02143024 is currently completed. Last updated 18 January 2020.

Are results published for NCT02143024?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-01-18 · How we verify

NCT02143024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Family-based Primary Care Intervention to Enhance Older Men's Depression Care

Completed NA Results posted Last updated 18 January 2020

What this trial tests

NA trial testing Family-based depression intervention in Major Depression in 23 participants. Completed in 31 December 2016.

Timeline

1 November 2015

Primary endpoint
31 December 2016

31 December 2016

Quick facts

Lead sponsor	University of California, Davis
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	1 November 2015
Primary completion	31 December 2016
Estimated completion	31 December 2016
Sites	1 location across United States

Drugs / interventions tested

Family-based depression intervention
Usual care plus educational materials

Conditions studied

Major Depression — all drugs for Major Depression →

Sponsor

University of California, Davis

Who can join

50 and older, male only, with Major Depression. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Depressive Symptoms Primary · baseline, 3 months, and 6 months

Patient Health Questionnaire (PHQ-9) scale; 0-27 scoring units; higher scores indicate more severe depressive symptoms.

baseline

Group	Value	95% CI
Family-based Depression Intervention	14.8	± 2.9
Usual Care Plus Educational Materials	15.3	± 4.1

3 months

Group	Value	95% CI
Family-based Depression Intervention	10.1	± 6.6
Usual Care Plus Educational Materials	13.0	± 7.5

6 months

Group	Value	95% CI
Family-based Depression Intervention	11.8	± 7.1
Usual Care Plus Educational Materials	13.3	± 6.3

Sponsor's own description

Despite the public health importance of clinical depression, more than 50% of depressed adults receive inadequate or no treatment, with even higher rates of under-treatment in men and minorities. Family members and/or friends often assist older adults in their health care and may help overcome barriers to formal care, yet there is a lack of primary care-based interventions that mobilize family members and friends to improve depression treatment. In partnership with a community-based clinic, this research will address this scientific gap by developing and then testing the feasibility and acceptability of a family-based intervention that can be delivered pragmatically in a primary care setting serving large numbers of older minorities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Major Depression

Currently open trials in the same condition.

NCT07031817 — Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Di · NA · recruiting
NCT07184697 — Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD. · NA · active not recruiting
NCT07463911 — Treatment Response In ECT Patients · active not recruiting
NCT06763081 — Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation · recruiting
NCT06781593 — Combining Light Therapy and CPAP in Depression · NA · recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02143024 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 18 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02143024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing